Non-steroidal anti-inflammatory drugs amid COVID-19 pandemic: An ally or an enemy?

Authors

  • Azhar Hussain Franklin University, Ohio
  • Jasndeep Kaler Xavier University School of Medicine, Oranjestad
  • Sohail Kumar Dow Medical College, Dow University of Health Sciences, Karachi
  • Dua Azim Dow Medical College, Dow University of Health Sciences, Karachi
  • Sundus Nasim Dow University of Health Sciences

DOI:

https://doi.org/10.3329/bjid.v8i1.49980

Keywords:

SARS-CoV-2; NSAIDS; ACE2; COVID-19

Abstract

As the current global pandemic of the novel coronavirus diseases 2019 (COVID-19) continues to rage, the scientific and medical worlds are working to establish an effective therapy against the illness. Recently questions regarding non-steroidal anti-inflammatory drugs (NSAIDs) as a potential therapeutic option for COVID-19 have surfaced. While some studies hint towards the possible benefit of NSAIDs against SARS-CoV-2 infection, the current body of evidence also sheds light on the potential risk of using NSAIDs in COVID-19 patients. Thus, the available literature does not provide conclusive evidence for or against the use of NSAIDs for treating COVID-19 patients. Given the limited data available, we suggest cautionary approaches for the public to avoid possible harm until further evidence emerges. NSAIDs should not be used as the first-line agents for COVID-19 unlessunder medical supervision. Moreover, patients with chronic inflammatory conditions should continue the NSAIDs as per their regular prescriptions.

Bangladesh Journal of Infectious Diseases 2021;8(1): 50-52

Downloads

Download data is not yet available.
Abstract
20
PDF
46

Author Biography

Azhar Hussain, Franklin University, Ohio

Doctoral Candidate of HealthCare Administration

Downloads

Published

2022-01-30

How to Cite

Hussain, A., Kaler, J., Kumar, S., Azim, D., & Nasim, S. (2022). Non-steroidal anti-inflammatory drugs amid COVID-19 pandemic: An ally or an enemy?. Bangladesh Journal of Infectious Diseases, 8(1), 50–52. https://doi.org/10.3329/bjid.v8i1.49980

Issue

Section

Perspective